Soon after the cloning of BRCA1 and BRCA2, traneach of these mutants was tested in the yeast twohybrid assay for interaction with EMSY. These experiscriptional activation domains were described in both ments showed that a short patch of 12 amino acids at proteins. One such domain is present in the highly conthe BRCA2 N terminus is required for transcriptional served exon 3 of BRCA2 ( Figure 1A ) (Milner et al., 1997) .
activation. The EMSY-BRCA2 interaction is affected by The importance of this domain in the tumor suppressor mutation of six of these residues. function of BRCA2 is suggested by the report of a breast To confirm the interaction between EMSY and BRCA2, and ovarian cancer family whose germline mutation was we used a bacterially expressed recombinant glutathishown to be an exact in-frame deletion of BRCA2 exon one-S-transferase (GST) BRCA2 (1-197) fusion protein 3 alone (Nordling et al., 1998 ), although such a deletion to pull down the radiolabeled in vitro translated N-termight also have general effects on protein structure and minal region of EMSY (1-478) ( Figure 1B) . The interaction function. The physiological role for a BRCA2 transactivawas also tested with transfection of the respective epition domain remains uncertain. However, it has recently tope-tagged mammalian expression constructs into 293T been shown that BRCA2 can stimulate transcription of cells, followed by coprecipitation and Western blotting androgen receptor-regulated genes in cooperation with of whole cell extract. EMSY (1-478) interacted specifihistone acetytransferases (Shin and Verma, 2003) .
cally with BRCA2 (18-60), corresponding to the exon 3 Here we identify a protein, EMSY, which binds BRCA2 activation domain ( Figure 1C ). We then generated two and like BRCA2 has functions associated with DNA rerabbit polyclonal anti-EMSY antibodies to short fragpair and transcriptional regulation. EMSY has the ability ments of recombinant bacterially expressed human to contact chromatin-regulating proteins that contain Collectively, these results demonstrate that EMSY is 18-46 of BRCA2 exon 3. a repressor protein which has the capacity to bind a We examined the EMSY binding site within the BRCA2 small epitope within the BRCA2 exon 3-encoded tranexon 3 activation domain with an alanine scanning mutascriptional activation domain and specifically silence genesis approach ( Figure 1A ). The interaction site was this activity. narrowed down to the BRCA2 amino acid region 23-46 with a deletion series (not shown). Each amino acid EMSY Relocalization to Sites of DNA Damage residue within this critical region of BRCA2 was then Immunofluorescence studies with the anti-EMSY antibody (Abcam ab123) showed that EMSY is nuclear, with mutated to alanine with site-directed mutagenesis, and simply being amplified as a passenger to Cyclin D1, a gov/genome/guide/human), and it reveals that three well-characterized breast cancer oncogene which lies cores are clustered within a 1.4 Mb interval. Cyclin D1 6 Mb centromeric to EMSY. and EMS1 are strong candidates for driving amplification at two cores within this cluster, whereas the candidate gene for the third (D11S97) is unknown.
EMSY Amplification Is Associated with a Poor Prognosis in Human Breast Cancer A further core is defined by the GARP gene (Bekri et al., 1997). The GARP amplicon lies 6 Mb telomeric to We then asked whether EMSY amplification is associated with clinical outcome by using FISH in tissue mithe other cores, a physical separation which may explain why this locus has the highest independent amplification croarrays (Kononen et al., 1998) of primary sporadic tumors sent to Vancouver Hospital during 1976 to 1990. frequency of all the amplicons on 11q13 (Ormandy et al., 2003). Strikingly, EMSY lies immediately adjacent to
Clinical data and outcome, including all breast cancer recurrences and deaths, were available for all patients. the GARP gene, within 0.1 Mb. Therefore, it must also be contained in this well-described breast cancer amplicon Amplification ratios for EMSY and Cyclin D1 were obtained by normalizing gene copy number against centro-( Figure 6A ).
To investigate whether EMSY is amplified in breast mere 11 copy number. FISH for EMSY gene copy number was successful in 551 of 928 cases. There was no differcancer, we used FISH (fluorescence in situ hybridization) to examine metaphase spreads from 28 breast cancer ence in survival between cases with and without EMSY data (p ϭ 0.79). cell lines. We also did some intraoperative touch preparations from five newly diagnosed sporadic breast priThis more sensitive FISH-based analysis showed EMSY amplification (copy number ratio greater than 1.5) mary cancers, and found one with gross EMSY amplification ( Figure 6B ). In the breast cancer cell lines, we in 70 of the 551 breast cancers (13%). In 49 of these there were more than 5 copies of EMSY per cell. Cyclin found that five of the 28 (18%) had EMSY amplification (Table 1, middle column). In one of these cell lines, mas-D1 amplification was seen in 78 cancers (14%), and was present in only a subset of cancers with EMSY sive amplification of EMSY was independent of Cyclin D1 ( Figure 6B, left panel) . amplification (42/70 [60%]), which again suggests that both genes are independent oncogenic targets; this proNext, we asked whether this genomic amplification of the EMSY gene results in increased expression of EMSY.
portion of Cyclin D1-independent EMSY amplification agrees exactly with the data obtained by Southern blotQuantitative RT-PCR confirmed that cell lines with EMSY genomic amplification also had the highest levels ting on a different set of sporadic breast cancers described above. of EMSY expression (Table 1, right column) .
In order to confirm that the EMSY amplicon could be Examination of records from the cases described above indicates that the median disease-specific surindependently amplified, we performed array comparative genomic hybridization (CGH) on key genes across vival was 6.4 years for node-negative cases with EMSY amplification (copy number ratio Ͼ 1.5), versus 14 years the locus: CCND1, EMS1, GARP, and PAK1, and FISH for EMSY (Supplemental Table S1 at http://www.cell.com/ for node-negative cases without EMSY amplification. Overall, patients with EMSY amplification had a worse cgi/content/full/115/5/523/DC1; see Figure 6A for a description of gene order relative to amplicon cores). We disease-specific survival compared to patients without EMSY amplification (p ϭ 0.002) ( Figure 7A ). Remarkably, found that in the SUM52 cell line, the amplification interval involved only EMSY and GARP, and not genes from this effect was confined to node-negative breast cancer patients (p ϭ 0.0004) compared to node-positive cases the more centromeric amplification cores, or PAK1 which lies immediately telomeric. This confirms previous (p ϭ 0.14) (Figures 7B and 7C) . A similar effect is seen on overall survival (data not shown). The effect of EMSY reports of independent amplification at this locus (Bekri et al., 1997).
amplification on survival in patients with node-negative disease remained significant in a multivariate analysis When the expression of EMSY and GARP was compared in the SUM52 cell line, EMSY was found to be presented below the graph in Figure 7B . We were also able to show that the survival of patients with EMSY overexpressed by 6-fold, whereas GARP was barely detectable. These results confirm that EMSY can be indeamplification was not affected by the presence of con- current Cyclin D1 amplification ( Figure 7B ). We conclude carcinomas (62/360) and 0% of low-grade or borderline ovarian cancers (0/110) (p ϭ 0.001). In contrast to breast that EMSY amplification identifies a subset of breast cancers associated with a poor prognosis.
cancer, we found that Cyclin D1 amplification (11%) was less common than EMSY amplification (17%), and EMSY was less likely to be coamplified with Cyclin D1 (40% EMSY's Status in Ovarian Cancer EMSY was assessed in ovarian cancers with tissue of EMSY amplification cases had Cyclin D1 coamplification). Thus, EMSY rather than Cyclin D1 appears to be arrays. Amplification was seen in 17% of high-grade The name of each of the 28 breast cancer cell lines analyzed in this study is listed in the left hand column. EMSY genomic copy number is recorded in the middle column. In the right hand column, EMSY expression levels are ranked, with the highest expressing cells at the top (real time PCR estimation of relative mRNA levels). EMSY expression was assessed using ABI TAQMAN real-time PCR in a subset of 24 of the cell lines in which EMSY genomic copy number had been determined. Two independent probes for EMSY were designed and gave similar results. The ranking shows that cell lines previously found to have genomic amplification of EMSY by FISH also ranked highest in EMSY mRNA levels. The expression study was performed blind on numbered samples and EMSY expression levels were ranked before the number codes were broken to identify the cell lines.
a more frequent gene amplification event involving 11q13 in ovarian cancers.
EMSY's Status in Non-Breast/-Ovarian Cancers
We also examined EMSY amplification in non-breast/ 
